Who are BioClin Therapeutics's investors?

BioClin Therapeutics's investors include HealthCap, Inkef, Sectoral Asset Management, Sofinnova Ventures, Ysios Capital.

How much funding has BioClin Therapeutics raised?

BioClin Therapeutics has disclosed $136M raised across 6 rounds.

Where is BioClin Therapeutics headquartered?

BioClin Therapeutics is headquartered in San Leandro, US.

BioClin Therapeutics

San Leandro, US · Founded 2010 · Delaware corporation · 7 known investors

Find your way into BioClin Therapeutics

624 people in our graph share verified history with the BioClin Therapeutics team — schools, employers, funds. One of them is your warm intro.

Pamela Kleinunlockedknows Steve Abella · together at Shasqi (overlapped)

×2knows the team · via RiboNova, Inc.

×3knows the team · via Axonis Therapeutics

×3knows the team · via Nitrase Therapeutics

×3knows the team · via Amgen

Biotech

Founders & leadership

Steve Abella Chief Medical Officer2017–2020Steve Abella is a physician and oncology specialist with over 35 years of experience in clinical research and biopharmaceutical development, including senior roles at Amgen and Gilead Sciences. He serves as Chief Medical Officer at BioClin Therapeutics, where he develops clinical strategies for oncology programs and advises biotechnology companies on regulatory pathways and development planning.

Graeme CurrieChief Operating Officer

Stephen W. Lau President, Chief Executive Officer, and TreasurerStephen W. Lau is President, CEO, and Treasurer of BioClin Therapeutics, a company he founded; previously held C-level roles (COO, CBO, CFO) at large biotechs and startups including Amgen, Anthera, and Innovent Biologics, and worked in biotech investment banking at Canaccord. He has led clinical development programs across oncology, immunology, neuroscience, and genetic medicine, and has experience in fundraising, licensing, and M&A transactions in the biotech sector.

Kenneth Schwartz Chief Medical Officer2013–2016Kenneth Schwartz leads clinical development and regulatory affairs at BioClin Therapeutics. He has spent his career overseeing small molecule and biologic clinical trials across multiple phases, including IND and NDA submissions, with regulatory experience in growth disorders, rheumatology, oncology, gastroenterology, and metabolic diseases.

Eric Yuen Vice President, Clinical Development2014–2015Eric Yuen holds an M.D. from the University of Chicago and completed neurology residency and postdoctoral fellowships at UCSF. He spent seven years as a faculty member and clinical researcher at the University of Washington before accumulating over 20 years of clinical development experience in the pharmaceutical industry, including senior roles as Chief Medical Officer at multiple companies (Ultragenyx, RiboNova, Inozyme, and Spirovant Sciences) and Vice President positions at Johnson & Johnson and Merck, leading drug development across rare genetic, neurological, psychiatric, pain, and oncology disorders.

Marten Steen Named on SEC filingManaging Partner at HealthCap

Christian RichardNamed on SEC filing

Joel Jean-MairetNamed on SEC filing

Fouad AzzamNamed on SEC filing

Joseph L. TurnerNamed on SEC filing

David KabakoffNamed on SEC filing

Board

Jack NielsenBoard director

Investors · 7

HealthCapreportedStockholm

How we know: funding news · biospace.com · Not right? Tell us

InkefreportedAmsterdam

How we know: funding news · biospace.com · Not right? Tell us

Sectoral Asset ManagementreportedMontreal

How we know: funding news · biospace.com · Not right? Tell us

Sofinnova VenturesreportedMenlo Park · $100K – $15M

How we know: funding news · biospace.com · Not right? Tell us

Ysios CapitalreportedBarcelona · $5.4M – $21.6M

How we know: funding news · biospace.com · Not right? Tell us

Also in the syndicate · 2

Life Sciences Partners (LSP)Tekla Capital Management

Funding

SEC filings, press & company announcements

$136M disclosed across 6 rounds · 2012–2019

$50MSeries BMay 2018 · 2 sources
HealthCap, INKEF Capital, Life Sciences Partners (LSP), Sectoral Asset Management, Sofinnova Ventures, Tekla Capital Management, Ysios Capital
Source ↗

▶$10MraisedJul 2019 · 10 investors · Biotechnology

Rule 506(b)